蛋白质组合调节:一种新方法治疗肌缩侧面硬化症 (ALS) 的治疗方法
Shao Feng Yu1, Kumar Paulvannan1, Dennis Solas1
1Prosetta Biosciences, Inc. 670 5th St San Francisco, CA 94107, USA.
概括
研究人员在蛋白质复合体中发现了一种针对蛋白质二硫化异聚酶 (PDI) 的新型小分子,为肌缩侧面硬化症 (ALS) 发病提供了一种新的机制. 这种化合物在各种ALS模型中显示出希望,可能揭示出新的治疗见解.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 肌缩侧面硬化 (ALS) 是一种进展性神经退行性疾病,其特征是运动神经元死亡.
- 它的病理生理学是复杂的和多因素的,目前的理解仍在不断发展.
研究的目的:
- 引入一种新的ALS病变发生机制.
- 为了研究一种新的类似药物的小分子序列,向蛋白质二硫化异合酶 (PDI).
主要方法:
- 现型查以识别新型小分子.
- 在细胞和转基因ALS动物模型 (虫,,小鼠) 中测试该化合物.
- afinity 染色法用于识别药物标.
主要成果:
- 鉴定的小分子在家族性和零星性ALS的细胞模型中表现出活性.
- 该化合物在携带各种人类ALS相关突变的转基因模型中有效.
- 结构-活动关系 (SAR) 的优化导致了艾滋病毒和ALS活动的分离,以及目标识别.
结论:
- 一种新型药物样小分子针对蛋白质复合体内的特定PDI子集,为ALS病变产生提供了新的视角.
- 这种化合物在各种ALS模型中的疗效表明了潜在的治疗价值.
- 这些发现可能会阐明与ALS病理生理学相关的失调恒温的分子机制.
相关概念视频
Amyloid Fibrils
11.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.7K
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K


